The result showed a significant OS in ACC, COAD, HNSC, LIHC, and KIRP with a significant PFS in BLCA, PAAD, LIHC, and UVM, which means that a higher threshold of FDX1 expression difference may be required in these tumors to optimize outcomes. The gene discussed is FDX1; the disease is adrenal cortex carcinoma.